Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Key Highlights
- ➤Q3 revenue $3.81 billion, up 6.9% year over year
- ➤Q3 adjusted EPS $4.78, up 14.5% year over year
- ➤Full-year revenue growth guidance raised to 5.9%-6.7%
- ➤Full-year adjusted EPS guidance raised to $18.30-$18.70
- ➤Four transactions announced or closed, expected accretive to year-one adjusted EPS
- ➤FDA approved PGDx elio tissue complete CDx for advanced melanoma
Expert Statements
Adam Schechter, Chairman and CEO of Labcorp
“Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance.”
Adam Schechter, Chairman and CEO of Labcorp
“We furthered our leadership in specialty testing by launching innovative tests for advanced melanoma, Alzheimer's disease, and hepatitis D, while expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses.”
Adam Schechter, Chairman and CEO of Labcorp
“As healthcare continues to be transformed by advances in science and technology, personalized medicine, and evolving consumer expectations, Labcorp is well positioned to capitalize on these trends and drive sustainable long-term growth.”
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance PR Newswire
* Results from operations for third quarter 2026 versus third quarter 2025: * Revenue: $3.81 billion vs. $3.56 billion, up 6.9% * Diluted EPS: $3.22 vs. $3.12, up 3.3% * Adjusted EPS: $4.78 vs. $4.18, up 14.5% * Raised full-year enterprise revenue growth and adjusted EPS guidance: * Revenue growth range of 5.9% to 6.7%; up 50 basis points at the midpoint * Adjusted EPS range of $18.30 to $18.70; up 18 cents at the midpoint * Advanced M&A strategy by announcing or closing four transactions; each are expected to be accretive to adjusted EPS in year one and return cost of capital by year three * Received FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma BURLINGTON, N.C., Oct. 28, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year financial guidance.
Get started
Create a free account to read the full story.